Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for November 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.U.S. Life …

Prevalence of prediabetes 18.0 and 24.0 percent among adolescents and young adults, respectively

Adjusting glucose thresholds for alarms linked to less time spent in hypoglycemia, hyperglycemia

Risk for MACE decreased with recovery from metabolic syndrome, while risk up with MetS development

Study shows mechanism of statins can induce onset of diabetes

Significant decreases seen for children aged 2 to 4 years enrolled in WIC state, territory agencies

Venlafaxine, amitriptyline use during pregnancy associated with increased risk for gestational diabetes

Risks increased for all-cause mortality, cardiovascular events, microvascular complications

Findings independent of adolescent obesity and further tied to diabetes diagnosis at younger age

Variation in prevalence of eye exams from 43.9 percent in Puerto Rico to 64.8 percent in Rhode Island